JPS59104314A - Novel plaster - Google Patents

Abstract

PURPOSE:A novel plaster that is made by adding a microhydro gel to an organopolysiloxane as a base component to effect dispersion, then adding the active ingredient thereto, thus having satisfactory adhesion and tackiness to skins and showing very good releasability, duration of action and percutaneous absorption. CONSTITUTION:An organopolysiloxane which is obtained by reaction between a diorganopolysiloxane having vinyl groups as its terminal groups and a viscosity of 600-700,000, preferably 700-70,000 centipoise and an organohydrodienepolysiloxane having active hydrogens on both chain terminals in the presence of platinum or its compound is combined wth a microhydro gel containing water as much as 100-500 times its own weight so that the water content of the organosiloxane becomes 0.1-80wt%, preferably 10-60wt% to effect dispersion, then pharmaceutically active ingredients are added. The resultant plaster keeps cool feeling for hours, further causes no side-effects and no pain on peeling off, too.

Description

[Detailed description of the invention]

The present invention has particularly excellent drug release and transdermal absorption, and
A new medical term that significantly alleviates the pain at 1 o'clock (
= J drug. Traditionally, patch therapy has been used in which drugs are contained in a tape or sheet-like material and the skin is covered for various treatments. It is made up of multiple layers of dead cells, and as a whole plays the role of a lipid barrier, so there is a problem in that it is difficult for a sufficient amount of the expected medicinal ingredient to be absorbed through the skin.Therefore, the drug must be contained at a surface concentration. There was a drawback that it was not possible. On the other hand, based on the knowledge that increasing the water content of the skin's stratum corneum reduces the barrier ability of the skin's stratum corneum and increases the drug absorption effect, the drug is contained in the Senda adhesive layer for 12 to 24 hours. Occlusive bandage therapy (OD
T therapy) is known, but this method does not allow effective drug release because the drug is difficult to spread and move through the adhesive layer, and long-term application may cause itching, irritation, and irritation.
This method still has disadvantages such as excessive whitening, etc., and is not a satisfactory method. In order to solve these technical problems, the present invention was developed after intensive research and various studies.The present invention is based on a diorganopolysiloxane whose terminal group is a vinyl group and an organohite whose terminal groups are active hydrogen atoms. Organopolysiloxane obtained by reacting rhodiene polysiloxane with platinum or a platinum compound in the presence of platinum or a platinum compound is used as a base component, and microhydrokel is dispersed in it. ■) Drug release and sustainability 2) Drug delivery to the skin Absorbency and sustainability 3) Appropriate duration of cooling sensation 4) Appropriate elasticity when applied 5) Adhesion to the skin 6) Appropriate adhesion to the skin 7) Pain during identification and plaster residue 8) We have completed the present invention by discovering that a patch can be obtained that satisfies conditions such as skin irritation such as itching, irritation, and excessive whitening. That is, the present invention uses a diorganopolysiloxane whose terminal group is a vinyl group as a base component of a patch.
The main feature is that the base component is an organopolysiloxane obtained by reacting an orkahydrodienepolysiloxane whose group is an active hydrogen ring in the presence of platinum or a platinum compound, and microhydrocels are dispersed in this base component. It is something. More specifically, the organopolysiloxane is one that is cured by hydrosilation, which is an addition reaction of hydrogen atoms directly bonded to silicon atoms in the diorganopolysiloxane in the presence of a platinum catalyst, and is a so-called two-component RT.
This is called V-rubber. In addition, the diorganopolysiloxane and organohydrodiene polysiloxane used to obtain the organopolysiloxane include K.
E 106-LTV (@Shin-Etsu Chemical), KE-103
RTV ((+1 Shin-Etsu Chemical), KE-104GEL [■
(manufactured by Shin-Etsu Chemical),
"T'5E-3032RTV (Qm manufactured by Toshiba Silicone), TSE-3402RTV (n manufactured by Toshiba Silicone), YE-5822 (■ manufactured by Toshiba Silicone), YE
-5818CI Sakaki Toshiba Silicone]. 5H-9583([1)l--1y', i'V:l-7
manufactured by), 5H-9555 (■1-- manufactured by Renricorn), 5
t(-9585 (manufactured by 111-Resilicone), etc., which are widely commercially available and can be easily obtained. In order to obtain the base component of the present invention, these can be appropriately selected and used in combination. Furthermore, the base component of the present invention will be explained in detail. Hereinafter, simply referred to as diorganopolysoloxane) and /ili (organohydrodiene poly/di2 chitin (hereinafter simply referred to as organohyde (cosienbolino 1) xane) in which both terminal groups have 11 hydrogen atoms are platinum or In the presence of the compound, the compound is stratified, and the viscosity of the diorganopolysiloxane used is 600 to 700,000 centivois. It is suitable for obtaining diorganopolysiloxanes, and preferably has a centivoise of 700 to 70,000. Various types of organohytrodiene polysiloxanes can be freely used. 1 to 1 part of organohytrodiene polysiloxane
By blending 100 parts by weight, preferably 2 to 9 parts by weight, a base component suitable for the present invention can be obtained. In the above-mentioned reactions, platinum or a platinum compound is used as a catalyst, and a sufficient effect can be obtained with a normal amount of the catalyst. The catalyst may be added separately from the diorganopolysiloxane and the organohydrodiene polysiloxane, or may be added in advance to the organohydrodiene polysiloxane. In addition, the reaction temperature of diorganopolysiloxane and organohydrodiene polysiloxane in the presence of platinum or a platinum compound is such that crosslinking and curing progresses gradually near room temperature, and as the temperature rises, crosslinking and curing becomes faster. The reaction temperature and reaction time must be set based on the desired conditions, but are usually 0 to 100°C, preferably 20 to 50°C.
It is °C. Further, the reaction time is within 24 hours, preferably within 3 hours. The base component of the present invention obtained by the formulation and method described in ``2'' breaks the general concept that two-component RTV silicone rubber has no tackiness, and has tackiness sufficiently suitable for patch medicines. It is something. Next, microhydrogel, which is one of the major features of the present invention, is used to create a transdermal absorption effect that is ideal for a patch containing the organopolysiloxane obtained in this way as a base component. The microhydrogel used here is produced by making a super absorbent polymer absorb water. Therefore, a water absorbing polymer is one that has a molecular weight of 10 to 1 in one shot.
, it absorbs 1,000 times more water and forms an aggregate of microkels, does not dissolve even when heated, and has the characteristics of being difficult to separate from water even under pressure or in a vacuum cleaner.C1 structure is hydroxyl group. By introducing a mild crosslinking bond into a water-soluble polymer having a hydrophilic group such as a carboxyl group or a salt thereof, the entire resin has a network structure and is made water-insoluble. Further, detailed examples of the superabsorbent polymers include a) starch graft-polymerized with acrylic acid, methacrylic acid, or maleic anhydride, or a crosslinked product of an alkali neutralized product thereof [for example, Wet IM-300, etc.] Self-crosslinking type alkali metal acrylate polymer obtained from an alkali metal acrylate or an alkali metal methacrylate [for example, ■ Iron Manufacturing Chemical System/Aqua Keep 43. Aqua Keep 103H, etc.] 3) Copolymer of α-olefin and maleic anhydride or its derivative, or a crosslinked product of its alkali neutralized product 2) Vinyl ester and acrylate copolymer [for example, Sumikagel 5-50. Sumikagel N-50, Sumikagel ll-100, etc.] e) To a copolymer of vinyl acetate, methyl vinyl ether, etc. and maleic anhydride or its derivatives) To a crosslinked product obtained by graft polymerizing acrylonitrile to starch or its alkali neutralized product (1) A crosslinked product obtained by graft polymerizing acrylonitrile to cellulose or its alkali neutralized product (1) A crosslinked product obtained by graft polymerizing acrylonitrile to cellulose or its alkali neutralized product; 1) Cross-linked with carboxymethylated with etc. 1) Cross-linked with dialdehyde, radiation, etc. 1) Modified with maleic anhydride, itaconic acid or crotonic acid I) Cross-linked with V-8 ) Copolymers of bifunctional compounds and acrylic acid; (b) Copolymers of acrylic acid, acrylamide, acrylonitrile, and their metals 1 to 11, and hinyl chloride and vinylidene chloride, which are treated with alkali. . These can be used alone or in a mixture of two or more to provide 10 to 1,000 times the scale, preferably 10
The microhydrogel used in the present invention is made by absorbing 0 to 500 times more water. Preferable effects can be expected by adding and dispersing the microhydrogel in such a proportion that the water content of the organopolysiloxane, which is a base component, is 0.1 to 80%, preferably 10 to 60%. In addition, the water content is 0
．． If it is less than 1%, the transdermal absorption effect of the drug, which is a feature of the present invention, will be weakened, and the cooling sensation during application will be poor, and if it is more than 80%, it will not have sufficient strength and will be more stable. The quality also deteriorates, which is not desirable. The present invention is the first to accomplish and achieve the unique formulation and method of enhancing the transdermal absorption effect by dispersing microhydrogel in organopolysiloxane having the above-mentioned adhesive properties. Now, the medicine component is blended with the orkanoborisiloxane base component obtained by the method and formulation described in section 2 and used as a patch. Medicinal J ingredients that are included in the present patch (Nu 1 drug) include, for example, salicylic acid, methyl salicylate, glycol salicylate, p-men1~-l, camphor, Hatsukaura, thymol, nicotinic acid hensyl ester, Capsicum extract, turnipsaicin, oxyphenbutacin, bentazoson, eptazoson, phenazole, mepiridul, piroxicam, hensotamine, tiarami 1. Bufexamanoc, acetaminophen, and ibubu 1 Copan, Alc 1
"Fenac, acemethacin, ketopml fen, flurhyp l-afT-n, diclof, nac, fenoproflon, pirub 1-1 fen, naproxen, sulindac, pesogizap I-J fen, indo'bufen,
Mehls J, #l-Lumetin, Methiazine acid, Prodecynoic acid, Pranob IJ Fen, Shincur, Fensifuan, Fentiadec, Diflunizal. Zomepirasoku, Pimepu I Kofuen, Hendazanoku. Skin irritants and analgesic anti-inflammatory agents such as Miroflofen, Amfenasoc, Suprofen and their ester derivatives: Central nervous system acting agents such as fluphenazine, thioridacine, diazepam, chlorpromazine, nitrasepam: Hydrocortisone acetate. HiF oral cortisone, prednisolone, doriamcinolone acetonide, dexamethasone phosphate, methylprednisolone, gyclorisine acetate. Methylprednisolone acetate, fluocinolone acetonide, dexamethacin acetate, dexamethacin. Fluoromesolone, hetamethacin sodium phosphate, hetamethacin, hecumetasone valerate, formocortal,
flumethacin pihalate, beclomethasone propionate,
Flutroxycortito', hydrocortisone butyrate, hetamethacin dipropionate. Fluocinonide, clohetasol propionate. Dinorcortoron valerate. Corticosteroids such as haldinonide, amcinonide, prednisolone valerate, etc.; Local anesthetics such as lidocaine, hensicaine, ethyl aminobenzoate, procaine hydrochloride, dibucaine, procaine, etc.: i
n#l diphenhydramine. [1ruf niramine, diphenylimidazole. Lorferramine maleate, glycyrrhetinic acid. Antihistamines and antiallergic agents such as l-lanilast and ketotifen: Hydrothiazide 2 Pen 10 Antihypertensive diuretics such as flunathiazide and reserpine: Ri 1 Antihypertensive agents such as conidine: Penicillin. Tetracycline, oxytetracycline, chlortetracycline, chloramphenicol. Sulfonoamy 1-. Oxytetracycline, fradiomycin sulfate, erythromycin, telacycline hydrochloride, fradiomycin, leucomycin, 7) chloride
"sporin, cephalexin, neophycin sulfate,
Bacitracin, kanamycin. Streptocyanin, Kentamicin, Gramidin S
Antibiotics such as , micamicin, colistin: hendilium chloride, nitrofurasone, nystatin, acetoflufamine, clotrimazole. Norlinx, Sulfamethidur, Tornafuchi-11
, pentamynon, ambotericin B, pyrrolnidoline, undecylenoic acid, miconadur, trichomycin,
Antibacterial and antifungal agents such as variotin, halopromidine, and cimazole hydrochloride: salicylic acid. Keratin softeners such as Mokukuru and Kurigo Robin: nitroglycerin, nitroglycol, isotsuruhi
Coronary vasodilators such as dinitrate, pababerine hydrochloride, dipyridamole, nifedipine, Herpet, Adalade: procaterol, meptin. Bronchial asthma agents such as pindolol, isoprotenol, and theophylline; Antiepileptic agents such as nitrazebam and mebropamate; anti-malignant tumor agents such as nibleomycin, aclacinomycin, adriamycin, pepleomycin, 5-fluorouracil and its derivatives, and mitomycin;
Hypnotic sedatives such as phenohalhicool, amoharhicool, Codin, Caripromal, and cycloharbital; Cardiotropes such as digitalis, dicoxin, and neuquinone; Testosterone, testosterone enanthate, triethisterone, methylestrenolone, mestranol, estradiol valerate, Ethinyl S 1 - Sex hormones such as Radimer: Hitamine △, Vitamin I] 1 Hitamine E
or other vitamins and vitamins such as ergocalciferol, cholecalciferol, off-1-thymine, and riboflavin butyrate; antitussive and expectorant agents such as codin diphosphate and pillpin; lysozyme and other anti-inflammatory enzymes; intuulin and others Antidiabetic agents: I) -, -Drugs related to Uu such as henisolamine, hestatin, lehamisole, carfenil, and platonin: Other anticonvulsants: Antimalarial drugs nib l costaglandin buccal: pancreatic bolmon. Examples include crude drug extracts, anti-ulcer agents, etc., and these medicinal ingredients may be used alone or in combination of two or more. Of course, these drugs can be blended alone into the base component, and can also be used in combination with polyethylene glycol, polyethylene glycol, hensyl alcohol, sotyl hensoe!...
Isopropyl myristate, polypropylene glycol, crotamiton. The drug may be used by dissolving it in a dissolving agent such as ethylene glycol, bunalene glycol, J.A.L. Furthermore, conventionally known transdermal absorption enhancers and stabilizers. Anti-aging agents, fragrances, antioxidants, reinforcing fillers. Additives such as bulking inorganic fillers and adhesives are added as necessary. Examples of additives include water-soluble polymers such as polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid, vinyl alcohol copolymers, polybutene, rosin, and ester gum. Examples include adhesives such as acrylic esters, bulking inorganic fillers such as silica, kaolin, talc, and zinc oxide. The medicinal ingredient is a microhydrogel dispersed in organopolysiloxane, the characteristic base component of the present invention described above (hereinafter referred to as the dispersion base component), in an amount of 100 i gI+
0.1 to 25 parts by weight, preferably 0.2 to 15 parts by weight
Parts by weight are added. Various additives may be blended as necessary in an amount of 5 to 20 parts by weight, preferably 7 to 15 parts by weight, based on 100 parts by weight of the dispersion base component. Next, the method of blending medicinal ingredients and additives will be described. The drug 9J component is preferably added in the amount described above after the microhydrogel described above is added and dispersed in the organopolysiloxane that is the base component of the present invention. Furthermore, if necessary, at the same time as adding medicinal ingredients, as long as the additives do not hinder the crosslinking and curing of the organopolysiloxane,
Or add it afterwards. Furthermore, the medicinal ingredients and additives may be blended in the same tank used to obtain the base component described above, and the temperature is sufficient to be within the reaction temperature for obtaining the base component. 1- Dispersion base component and medicinal ingredient obtained as described above,
Optionally, the mixture of additives is a flexible support, such as polyethylene, polypropylene, polybutadiene, ethylene-vinyl acetate copolymer. 9 Porous materials made of films or sorted materials such as polyhinyl chloride, polyester, nylon, etc. 1.
- Doctor Blade, Dr. Lol Chi - Q) Using a coating spray J machine, 50H-+ ~ 2 Soen, preferably 100r, 1 ~
Spread to a thickness of 1 dragon, at room temperature to 150°C, preferably 4
Crosslinking and curing is performed by heating at 0 to 80°C for 3 minutes to 24 hours, preferably 15 to 40 minutes. Thereafter, the surface is covered with release paper, cellophane, or a plastic film such as polyethylene or polypropylene, and the object of the present invention is obtained by cutting it into a desired size, or once it is After spreading on a support, the above-mentioned heating and crosslinking curing treatments are performed to obtain the desired synthetic resin. The object of the present invention can also be obtained by covering with a support such as cloth, pressing and transferring, and cutting into a desired size. The above methods can be appropriately selected depending on the intended support. Next, the effects of the patch of the present invention will be described. The patch of the present invention obtained as described above has appropriate adhesion and adhesive strength to the human skin, and due to the water retention ability of the microhydrogel, the cold sensation lasts for a long time. Even if you continue to apply it for a long time, there are no side effects such as discomfort, and there is no pulling of the hair or destruction of the dead skin when it is removed. It has great characteristics such as strength and adhesive strength.It also has very good drug release, persistence, and transdermal absorption, making it extremely useful industrially as an ideal patch drug. As mentioned above, the effects of the present invention are, of course, due to the characteristic base components.The above effects will be explained in the following test examples.In the test examples, examples and reference examples Test Example I: Comparative Test on Usability Test Examples 1 and 2 of the present invention, commercially available anti-inflammatory analgesic plaster A (base As natural gono,
- synthetic rubber, the drug contains methyl salicylate) and poultice B (gelatin) - kaolin (based on water-soluble bacteria molecules, the drug contains methyl salicylate). It was applied to the surface of the forearm and peeled off after 8 hours.The following items were tested and evaluated.The results are shown in Table 1. Compared to Plaster A and Ba Nobu Agent B, it was found to be significantly superior to Plaster A and B-Nobu Agent B, which combines the advantages of both, which suggests the usefulness of the present invention.Test Items A) Cold Sensation Those with a sensation...◎ Those without a cold sensation...× Mouth) Fast-acting (time to feel irritation) within 5 minutes
...◎ Within 5-10 minutes...O 10 minutes or more ...× C) Persistence (time until irritation disappears) 4 hours or more
・・・◎ 2 to 4 hours ・・・0 Within 2 hours ・・・× d) Adhesiveness Sticks well through the application ・・◎ Edges are peeled off・○ More than half peeled off・・×Po) Strength of stimulation: Very strong ・・・◎ Strong ・・・○ 1 Stimulus ・ ・ ・ ×
to) Peel off

[When the pain comes off easily -Vru...◎ I feel pain...O There is strong pain...× 1,) Re-applying the 100 patches when peeling 1 5 on the same side・◎ Does not stick ・・× Table 1 As is clear from the above results, the adhesive patch of the present invention had a cooling sensation, immediate effect of 11 [, persistence, adhesion, and strength of irritation]. Pain during abrasion, abrasion+? Good results were also obtained for reapplying at 111 hours. Test Example 2 Water Retention Comparison Test Using the anti-inflammatory and analgesic patch according to the present invention obtained in Examples 1 and 2 and two types of commercially available anti-inflammatory and analgesic poultices (one C-paralysis), 25'c, 50 Ni lj'1 in an atmosphere of %RH
．． W, and the residual moisture rate was determined based on the weight change. The results are shown in Figure 1. (In the figure, 1 indicates Example 1, 2 indicates Example 2, C indicates commercial product C, and 1 indicates commercial product.) As is clear from these results, the product according to the present invention is commercially available. In comparison, it had high water retention. Figure 1 4 8 12 16 20 24 Hours (hr) Test Example 3 2X on the back skin of 5 healthy male volunteers as human percutaneous absorption test subjects
2CI+! The product of Example 3 according to the present invention and the product of Reference Example 1 cut to a size of The transdermal absorption rate of the drug (%
) was sought. The test results are shown in Table 2. However, the product of the present invention had good drug release properties and transdermal absorption, and was more than suitable for the useful life of the present invention.Table 2 1) Average value Standard 4 + Error Test Example 4 The elution of indomethacin into water was measured using the underwater release test Example 4.5 and Reference Example 2. Each sample was cut into 4 x 4 cJ, immersed in pure water at 30 ° C. The relationship between immersion time and release rate (%) was investigated. Figure 2
The results are shown in Table 1, and Example 4.5 according to the present invention showed a much higher release rate than Reference Example 2. Figure 2 1 2 3 4 5 6 7 8 9 1 part 1 Refining time (hr) As is clear from the test results below, diorganopolysiloxane and organohyto-rodienborsi + 1 xane were mixed in the presence of platinum or a platinum compound. The present invention, which is characterized by using organopolysiloxane obtained through reaction as a base component and dispersing microhydrokel therein, can be said to be a new type of patch that eliminates the drawbacks of conventional patches. . Hereinafter, the present invention will be explained in more detail with reference to Examples. However, it goes without saying that the present invention is not limited to the examples. In the examples, all parts indicate parts by weight. Example 1 T S E- which is a diorganopolysiloxane with a vinyl end group of 4,000 centivoids at 25°C.
3032RTV (manufactured by 91 Toshiba IJ: I-7) 1
00 parts and 10 parts of platinum-containing YE-5822B (manufactured by Toshiba Silicone), which is an organohydrodiene polysiloxane having active hydrogen atoms on both end groups and having 250 centibodies, were mixed by stirring at 30°C for 10 minutes. On the other hand, 45 parts of Sumikagel S-50 (01 manufactured by Sumitomo Chemical Co., Ltd., J made by absorbing 200 times its own weight in distilled water) was added to the Orkapp polysiloxane mixture and well dispersed. Then, 6 parts of l-menthol was added. , 6 parts of methyl lythate, and 5 parts of camphor were added and mixed for 20 minutes to make it homogeneous.The resulting mixture was spread on a water-impermeable nonwoven fabric to a thickness of II. The product was cured by heating for 25 minutes, and the surface was covered with cellophane and cut into the desired size to produce a product. When this product was applied to the human body, it had a medicinal effect and a lasting cooling sensation, making it an anti-inflammatory and analgesic patch (= J agent). Example 2 KE~1 is a diorganopolysiloxane having a vinyl group as an end group of 4,000 centipo-is at 25°C.
061TV (manufactured by f-kilit Etsu Chemical) 100 copies and 25°
7 parts of platinum-containing organohydrodiene polysiloxane having C and 250 centivoices and both end groups having active hydrogen atoms (7)YE-58228Cue) manufactured by Toshiba Silicone were stirred and mixed at 30°C for 10 minutes. -Kasan Ueno l-IM-300 (f+1 manufactured by Sanyo Chemical Industries)
was made to absorb 200 times its own weight of distilled water to form a microhydrokel. 80 parts of this microhydrogel was added to the mixture and well dispersed. Next, p-menthol IO part,
10 parts of methyl salicylate and 5 parts of camphor were added and mixed for 20 minutes to make it homogeneous. The resulting mixture was spread on a water-impermeable nonwoven fabric to a thickness of one fin, heated for 30 minutes to harden, the surface was covered with a polyethylene film, and the product was cut into a desired size. When used on the human body, the result was the same as in Example 1. Example 3 K I-, a diorganopolysiloxane with vinyl end groups, 4,000 centivoices at 25°C;
-106LTV (f41 Shin-Etsu Chemical) 100 copies and 2
TSE-3032R"VV-B, an organohydrodiene polysiloxane containing active hydrogen atoms at both end groups and containing 600 to 000 centibodies at 5°C.
(manufactured by Toshiba Silicone) and 9 parts were stirred and mixed at 25°C for 10 minutes.
M-300 [11 manufactured by Sanyo Chemical Industries, Ltd.] was made to absorb 150 times its own weight of distilled water to form a micro hydrokel. Add 60 parts of this microhydrokel to the mixture,
4't Saichita. Next, 5.7 parts of ketoprofen dissolved in 15 parts of ethylene glycol was added and mixed for 15 minutes to make it homogeneous. 500mm thick
The mixture was spread on a polybuxene sheet of Section M to a thickness of 100 Pl) and heated for 25 minutes to cure, and then the surface was covered with polyethylene 7 film to prepare a product. Example 4 YE-5E is a dicappolysiloxane with a vinyl terminal group, 70,000 centivoices at 25°C.
i 2 G (manufactured by O(1) Higashiguchi Solicon) 100 parts and 600 to 1,000 centivoices at 25°C, platinum-containing organohydrodiene polysiloxane having active hydrogen atoms at both end groups (7) 1゛5E-3032R
TV-13 (!11 + Toshiba Silicone: l 8r7
1+ and were stirred and mixed at 25°C for 20 minutes. On the other hand, Aqua Key 143 (manufactured by Seitetsu Kagaku Co., Ltd.) has 250 of my 111.
It was made into a microhydrokel by absorbing twice as much distilled water. 80 parts of this microhydrogel was added to the mixture and well dispersed. India dissolved in 6 parts of crotamiton
Added 6 parts of methacin and mixed for 10 minutes until homogeneous. The resulting mixture was spread on a water-impermeable nonwoven fabric to a thickness of 20 mm, and the surface was covered with cellophane to prepare a product. Example 5 'T' S is a diorganopolysiloxane with vinyl end groups of 4,000 centivoids at 25°C.
E-3032RTV full YE-5822B (@Higashiguchi Silicone) made by Toshiba Shihigashiguchi Silicone 000i and platinum-containing organohydrodiene polysiloxane in which both end groups of 250 centivoice at 25°C have active hydrogen atoms (@Higashiguchi Silicone) 7 parts were thoroughly mixed at 45°C for 20 minutes.Meanwhile, Sumikagel N-100 (manufactured by Sumitomo Chemical) was made to absorb 200 times its own weight of distilled water to form a microhydrogel.62 parts of this microhydrogel was added to the mixture. was added and dispersed well. Then, 5 parts of crotamiton/81W
Add 1 liter of indomethacin and mix thoroughly for 30 minutes. The resulting mixture was mixed with polyphthalene = 1.
The mixture was spread to a thickness of 200 parts mL, heated and cured for 25 minutes, and then the surface was covered with release paper to prepare a product. Example 6 KE-10 is a diorganopolysiloxane with a vinyl end group of 1,100 centivoids at 25°C.
31? TV ((4(1) Shin-Etsu Chemical Co., Ltd. 3100 parts and 602 cm voice at 25゛c, both terminal groups have active hydrogen atoms) 1" diene polysiloxane platinum-containing Yl-5822B (ill Toshiba (manufactured by Higashiguchi Corn) and mixed with a trowel at 50°C for 10 minutes (W).Meanwhile,
Sumikagel S-50 (manufactured by Sumitomo Chemical) has a weight of 20
It was made into a microhydrokel by absorbing 0 times the amount of distilled water. Add 70 parts of this microhydrokel to the mixture and mix well.
1&Sa-Uta. Then, to 10 parts of diethyl sebacate, 5.2 parts of flurhyprofen, which had been grown in 7 volumes for 1 year, was added.
Mix well for 5 minutes. The resulting mixture was placed on a nylon support (trade name: Niai Nil N-1070 Asahi Kasei M) for 10 minutes.
It was spread to a thickness of 0 parts m and heated and cured for 25 minutes. The surface was covered with cellophane and the product was cut into a desired size. Example 7 X-32-465, a diorganopolysiloxane with vinyl end groups, LL02 centipoise at 25°C
-2A (-Shin-Etsu Chemical Education) 60 at 25°C for 100 copies
2 centipoise organohydrodiene polysiloxane with active hydrogen atoms on both end groups and platinum-containing X
-32-465-2B (A41r (#W Chemical) 9
5 uB was added and mixed with stirring at 25°C for 10 minutes. On the other hand, Sunwet IM-300C (manufactured by Sanyo Kasei) was made to absorb 300 times its own weight of distilled water to form a microhydrogel. adding 65 parts of this microhydrogel to the mixture;
Well dispersed. Next, 0.05 part of hetamexone valerate and 1 part of propylene glycol were added and mixed thoroughly for 20 minutes. The resulting mixture was spread on release paper to a thickness of 100 mm, heated and cured for 30 minutes, covered with a polyethylene film, pressure-transferred, and cut into desired sizes to produce products. Example day: KIA is an orkahydrodiene polysiloxane having a hinyl terminal group with a diameter of 700 centivoids at 25°C.
-104GEL (f41 Shin-Etsu Chemical) 100 copies and 25
10 parts of platinum-containing Catl 04 (1111 manufactured by Shin-Etsu Chemical Co., Ltd.), which is an 80 centivoice polysiloxane in which both end groups are active hydrogen atoms, was thoroughly mixed for 10 minutes at 20°C. . On the other hand, Sumikagel S-50Cnl (manufactured by Sumitomo Chemical) was made to absorb 250 times its own weight of distilled water to form a microhydrogel. Next, 5.5 parts of polyvinyl acetate and 4 parts of sopiridamol dissolved in 8 parts of ethyl alcohol were added, and the mixture was mixed uniformly with 15 parts of polyvinyl acetate and 4 parts of sopiridamol.
The mixture was thoroughly mixed and stirred for a minute. The obtained mixture is made into a non-woven fabric 1
00. The film was spread to a thickness of 100 ml and cured by heating for 35 minutes. The surface was covered with release paper and the product was cut into a desired size. Example 9 KE-106L, a diorganoborisiloquine with a vinyl end group, 4,000 centipoise at 25°C
TV (@Shin-Etsu Chemical) ■ YE-58, platinum-containing organohydrodiene polysiloxane with active hydrogen atoms at both end groups, with 00 parts and 250 centivoices at 25°C
22B (@Higashiguchi Silicone) 9 parts were stirred and mixed at 40°C for 10 minutes.Meanwhile, Sumikagel N-100 [
(manufactured by Sumitomo Chemical) was made to absorb 300 times its own weight of distilled water to form a microhydrogel. Add this microhuman to the mixture.
50 parts of Logel was added and well dispersed. Next, 4 parts of Alclofenac dissolved in 1-5 parts of diisopropino D adipe was added and mixed well for 20 minutes. The resulting mixture was spread on a polybutadiene sheet to a thickness of 100 mm and cured by heating for 20 minutes. The surface was covered with polyethylene film and cut into a desired size to produce a product. Example 10 25°CT: 1,012
465-2△ [(manufactured by Kikushin-Etsu Chemical) 6 at 25℃ in 100 parts
Jt is an organohydrodiene polysiloxane with active hydrogen atoms in both end groups of 02 centibodies and does not contain platinum.
NoX-: 32-465-2B CN1r Shin-Etsu Chemical] 1
00 parts and stirred and mixed at 30° C. for 5 minutes. On the other hand, Sumikagel S-50 (II) manufactured by Sumitomo Chemical] has a weight of 250
It was made into a microhydrokel by absorbing twice as much distilled water. 100 parts of this microhydrogel was added to the mixture and well dispersed. Next, 9.7 parts of slightly dissolved Flurubip 1"fen was added to 15 parts of Chlorami 1-F and mixed for 15 minutes. The mixed mixture was spread on a water-impermeable nonwoven fabric to a thickness of 1 wn, heated for 20 minutes to harden, and the surface was covered with a Ceren-J fan and cut into desired sizes. Product Toshinoko. Reference Example 1 A known poultice with the following formulation was prototyped and designated as Ketoprofen-containing poultice Reference Example 1. Base component: Seratin 7 Carpoquin methylcellulose 2 Borihinyl alcohol 3 Kaolin clay
Titanium oxide 5 water
35 Ketoprofen 3 Ethylene Glycol 5 Glycerin 20 (Total 100 parts) Reference Example 2 A known poultice was trial-produced with the following formulation, and an indomexone-containing poultice was made. Composition: Seratin: 10: Borihinyl alcohol: 3: Glycerin
2゜water 38 kaolin clay 20 titanium oxide
4 carboxymethylcellulose
2-in-1 Methacin 3 (Total 10011 ri) Procedural official document (method) 1. Indication of the case 1982 Patent Application No. 198253 2. Title of the invention New patch drug 3. Relationship with the person making the amendment ・Patent 1iIIT person postal code 8
41 4. Date of amendment order: February 22, 1981 (Morning) 1111 t! t 1, Invention of the invention, name of new inkstone paste, 1 drug, 2, claim 1, the tree v11"11 uranium (or hyur group, shiolkanoborisoshi 1 gizan, and ryohui I/lA 1 group are active The hydrogen atom 1-L1 diembolyzed 14-nithane is reacted with the presence of platinum or a platinum compound, and the 1-L1 diembolyzed 1-L1-xane is reacted with the base component and U.
7-(, 1 honey for 10 kels in 11 minutes!,
It is also characterized by the fact that it contains mulberry-effective ingredients. 2. Is the dioxane 1? -1-Zan's rod, 1 piece, is 600
〜'700.000 centiboino, -ζcf) A] A new patch of the first layer of the patent claim characterized by the following:
]medicine. ;3. Invention lI'1'1111ノ&i! 'u Akiramoto's 19th invention is particularly excellent in drug release and transdermal absorption, and =:
] i/II store time 昂 1 knob I':) l pleasantly relaxed j: Ii parent 1, k 1 woman month month 1 ancient (, 1 foot ζ closed, J ≦+4>. Traditionally, therapy has been carried out in which drugs are contained in a tape-like material or a sheet-like material to cover the skin and perform various treatments. ~ It is made up of multiple layers of dead cells filled with linox and lipids, and as a whole plays the role of a lipid barrier, so there is a problem that a sufficient amount of the expected medicinal ingredients are absorbed from the skin 1M and the gel 1F is absorbed. , therefore the drug should not be contained in the quotient '6'l'4&J
There are two people who have some drawbacks. On the other hand, based on the knowledge that increasing the water content of the skin's stratum corneum lowers the barrier ability of the skin's stratum corneum and reduces drug absorption, the pressure-sensitive adhesive layer containing drugs 12
A sealed package that is pasted for an hour or 24 hours (old law (OU))
T therapy) is known, but this method also has the disadvantage that it is difficult for the drug to spread and move through the adhesive layer, so self-effective drug release is not achieved, and long-term application may cause itching, irritation, This method still has drawbacks such as excessive whitening, etc., and is not a satisfactory method. In order to solve these technical problems, the present invention has been developed through extensive research, and the results have not yet been found! I group or hinyl group organoborisi 1''xane and both groups I/11
,l,! i! The presence of platinum or a platinum compound is reacted with 4-1 atoms of active 111 water and 4-1 atoms of organo-hydrogen in the presence of platinum or a platinum compound.
The potassium component is based on xane, and Miku L1hi1-1'' Kel is dispersed in it! 1) Drug release property, R1'lij property 2) Absorption property and persistence of drug skin + fi'-1; 3) J-shaped cold (・δ 1.1 multi-64) term Example ■, J white j law of ~ 11t-5) Denseness to the skin j^ 6) To the skin 1 west) 匈j, suna adhesiveness 1) +4. ll+411 o'clock Q month if th and・
1 body left 8) 1 hour of skin with rough spots, excessive whitening, etc.
'till' Go to Ino 1 of the output, (+'Ni
He discovered that it was possible to obtain an additional patch, and completed the invention, which led to Sony4). A-19+] The invention is based on the base component of Hesai Mulberry - C1
Furthermore, 1°) 1nl J4'=: or dicanoborin lokirin, which is a hinyl group, and l::°,'l) J:
2'l pain 1i (II) The presence of platinum or a platinum compound with orkanoborisiloxane, which is a hydrogen atom, is reacted with orkanoborisiloxane as a base component. The major feature of the silokanoboriso-1 coxane is that the hydrogen atom directly bonded to the silicon atom in the silokanoboriso-1 coxane is further characterized by the presence of a platinum-based catalyst. It refers to a rubber that undergoes b-furthering by the addition of hydrosilane which undergoes a reaction, and is called a two-component type R'l' V rubber. As a siloxane polysiloxane and an organohylic acid polysiloxane (Hani 1) 06-Ll'V
C (4II Shin-Etsu Chemical), KEIO3RT V ((
l) + Shin-Etsu Chemical], KIF, -104Gl 1,
[(Manufactured by Shin-Etsu Kate), X-32-465-2△, 21
3 [(III Shin-Etsu Chemical II, KE-1300R
1'V C (fil Iba Etsu Chemical), YE-5626N
Scoop East Exit Silicone Hole IJ), '1'5IC-30
3219TV ((Made of silicone at the east exit), “f”
5E-3402RTV (11 manufactured by Toshiba Silicone), Y
J-5822 ((4η Toshiba Series): 1.Y15
5B18 ((manufactured by Higashiguchi Silicone Co., Ltd.).
1, 5ll-9t'l 85 [1111) l. manufactured by Lenoli I Norn], etc., and ・L is commercially available. In order to obtain a base component, these are selected and combined as appropriate. Orkanoborisilyl:J-xane, which is used as a base component in medicines, has a terminal group or a hinyl group, orkanoborisilyl:J-xane (hereinafter referred to as "orkanobori-iso-IJ-kitotan" in 1-1), and both terminals, i41λ, 1
, is ll'i 111 Mizuhiki, there is an organohigh l:'
1J-1-
1)) is a platinum or platinum compound 1-1-, anti-Ire, s-IJ (ij7).
The viscosity of the lean material is ('+ The organohytrodiene polysiloxane can be used freely for various lamps. Both of the above contain 1 to 1 coxane of the organohytrodiene polysiloxane to 10 parts by weight of the dicappolysiloxane. By adding 100 parts by weight, preferably 2 to 9 parts by weight, it is possible to obtain an increased base component than that of the present invention. In the above-mentioned reactions, platinum or a platinum compound is used as a catalyst. , a sufficient amount of electricity can be obtained with an oil-tight amount of catalyst.
Separately from the
-) It may be used by pre-containing it in diene polysoloxane. In addition, the reaction temperature between the dicappolysiloxane and the organohytridienepolysiloxane due to the presence of platinum or a platinum compound may be too high for the progress of crosslinking and curing at room temperature. -i
Since crosslinking and curing become faster as the temperature rises, the reaction time per reaction time must be set based on the desired conditions, usually υ~] flO'c, preferably The temperature is 20-50°C. Also, anti-L+-1 time is 24
J) within an hour, preferably within 3 hours. By using the formulation and method described in Section I, i! The unique base component of the present invention breaks through the common notion that two-component R'VV silicone combs have no tackiness, and has tackiness that is sufficiently suitable for a single patch. It is something to do once. Next, in order to achieve the transdermal absorption effect ideal for a patch (-J drug) containing the thus prepared orcanoborisol l-1-1-kimanganese as a base ingredient, the major +14 features of the present invention are as follows. Mikul, which is one, is added to 1 and 1 kel. Mitsu 1': 2 kel used here is il.
'l+water absorption 1'l iN+water absorption into molecules 1I
It is made by VIJ. What is commercial water absorption, IJ, and molecules? 111 ji! It absorbs up to 1,000 cans of water and forms an aggregate of 1,000 cans of water, which does not dissolve even when heated and has the characteristics of being able to release water even under pressure of 1. One of them is ζ, structurally, a hydroxyl group. By introducing a mild cross-linking bond into a water-cooled polymer having a hydrophilic group such as a carboxyl group or a salt thereof, the entire resin can be made into a fine-grained structure, making it suitable for water-cooling. A detailed example of highly water-absorbing Ji molecules: A) A cross-linked product obtained by polymerizing starch with acrylic acid, methacrylic acid, or maleic anhydride, or its alkali neutralized product [for example, ++1 Sanyo Kasei Co., Ltd., Zanueno 11M300, etc.] Self-crosslinking type acrylic acid alkali metal salt type compound obtained from acrylic acid alkali gold In salt or methacrylic acid alkali metal salt [Mona &;J:' f+1 Iron Manufacturing Co., Ltd., Aqua Keep 4S , Aqua Keep 10 S H, etc.] c) A copolymer of α-olefin and maleic anhydride or its derivative, or a crosslinked product of its alkali neutralized product; 2) A copolymer of hinyl ester and acrylate [for example, Sumikagel] 50, Sumiki Reel N-50, Sumikari/Shi N-100, etc.) To the J-1 compound of hinyl acetate, nonalhinyl ether, etc. and (II (hydromaleic acid) or its derivatives) ) Craft polymerization of acrylonitrile to starch, 2. 4. Alkali neutralized product.
Cross-linked product 1-) Clat polymerization of acrylonitrile to Cell 1-J-S: Monomanoko is a cross-linked product of the alkali neutralized product = 7-) Starch is monomerized with monochrome 1. Carbogin methylated with acetic acid or the like is cross-linked with Polmarine or the like.1. 1) J'VA is cross-linked with Sialczych IS, radiation, etc. 1) Maleic anhydride 11 (, itaconic acid or rill1-
7 acid te * ('I shi), 2 I) V8 4tj l-7
E) Copolymer τ of bifunctional compound and acrylic acid
Acrylic acid, acrylamide 1. Examples include those obtained by treating a copolymer of acrylonitrile, its metal salt, hinyl chloride, and hinyritene chloride with an alkali. These can be used alone or in two volumes -1-
By mixing 1,000 to 1,000 times its own loss, preferably 100 to 500 tons of water, it is made into the micro-hydrogen used in this application. 1-Loquel is added and dispersed in such a proportion that the water content of the base component Orkapolysiloxane is from 0.1 to 0.0%, preferably from 10 to 60%. , favorable results) can be expected. still,
If the water content is less than 0.1%, the effect of transdermal absorption of the drug, which is a feature of the present invention, will be compromised, and the cooling sensation during the application will be undesirable. -1- does not provide sufficient strength and also has poor stability.
Both are unfavorable. -] The present invention was the first to achieve the unique formulation and method of increasing transdermal absorption toughness by dispersing microhydrogel in organoborisilixane with adhesive properties as mentioned above. be. Now, the λ black 1-'+- 1-2-ole-containing orkanoborisil coxane base component obtained by the above-mentioned method and formulation is blended with mulberry and used as a medicinal drug. Book 1 ++ i patch (t As an active ingredient used in medicine - (
For example, salicylic acid 1 menal lylicylate -IJ-
Linal acid, L/S: 1-L, L-menthol, camphor, Hatsuka lsan, thymol, 22+-J-nic acid hensyl ester Ukarashikonigisu, SoJ psaicin, Oxyfurl
Nftazone, Penctusin, Eptasocin, Fuenazo-
Lu, Mepirisol, Viloxocam, Hencitamine, Ciarami 1, Sofexamasoc, Acetaminophen, and Ibupu 1'' Fen, Alc! Fenac, Acemethane, Ketobrof Zun, Flurhyprofen, Shiku L1
Fenac, fenoprofen, pilp 1 cofen, naprogysen, sulindac, henoxap 1'fen, indobufen, mefenamic acid, tourmenan, methiacic acid, pyrucotidic acid, branoprofen, cincur, fenfufen, fennaazasoc, difluni. Tsumepiratsuku, Pimep 1,1 Fen, Hendazanoku. Miji 17'l Coffen, Amfenanok, Sprofen as well as these Q month Nistil-induced 7jI skin IF! '
! I! II Intense drugs and analgesic anti-inflammatory drugs: Fluphenazine,
Thiolitanone 5 Central nervous system acting agents such as cyacepam, riLJRupjiJinshin, and 21 cihibam: human ucortidunes acetate. H[-L+cortisone, prednisolone, triamunolone or 1,21, dexamethone phosphate, methylbutylene 1'nisolone, J rin'on on white. Methylprednisolone acetate, fluoran 1-acetonitate, 11-sho acid dexamec-cin, dexamethasone. Full first comesolone, hetamethacin phosphate,
Hetamexone, Hetamexone Valerate 3 Polmocortal, Flumexone Pihalate. Heclomethasone pionate, fludroxycortide. Hydrocortisone dipropionate, hetamethasone dipropionate. Fluocinonite, clohetapur propionate. Corticosteroids such as diflucort valerate, haldinonide, amcinonide, valerate, etc.:
Litcaine. Topical hemp such as hensicaine, ethyl aminobenzoate, propylene hydrochloride, dibucaine, and cocaine+
llrjV punishment; diphenhydramine hydrochloride. 1-1 phenylamine, shift nylimidasol. -7 Rein acid 1: J Ruff. Arlamin, clythyllenanoic acid. 1-Antihistamines and anti-allergic agents such as Ranilast, GeI and Tifuen: Hytrozaiazide], Bento 1 Coflunazaazide, Reserpine, etc.; I-pressure diuretics:
1. Anti-West pressure agents such as herring: Penicillin. Detrazycline, oxytetracycline. ri L1 lute I lazycline, ri 1 column phenicol. sulbonamyl, oxidase l~razycline, fracyonecin sulfate, conilis 1comycin, 1; fi
frJ Te1rasa, icrin, fufusi'mycin, Ico-l-in-isin, Cepha-11-sporin, cephalexin, neoma-isin sulfate, hashii-lacin, kanamain. Antibiotics such as Streso°1 Mine, Gentanisin, Gutumidine S, Mikamycin, -J Listin: Henzalkonium Chloride, Elm Furazon, Nyscutin, Acetoflufupmin, Clo I/Limassol. Narisix, Sulfur Methysol, 1-Lunafuti-1
・Pentamycin, amphotericone +3, pyrrolnidoline, undecylenoic acid, miconasole, 1-comycin, variotin, halop 1'' sewing machine, I! 11
Antibacterial and antifungal agents such as acid cimasol: salicylic acid. Keratinizing agents such as Mokukuru and Cryzarobin. Coronary vasculature agents such as nitrochrycerin, nitroglycol, isosolhydrinitre-1, papherine hydrochloride, dipyrytamol, nifedipine, Herbessa, Acra-1, and tonic agents: procaterol, meptin. Bronchial asthma drugs such as pintolu, ]-ol, isoprotenol, theophylline, etc.: Antiepileptic drugs such as nitrasebam, mef-1-1bamate: bleomycin/, acrasinone, etc.
Icin, adriamycin, vebleominone. 5-Fluoro uracil and its s1 form. Anti-neoplastic agents such as mitomycin: Phenohalchtal. Amohar hital. Hypnotic sedatives such as Codin, Caliph 1' Mar, Nku U Harhital, etc.: Nokitalis, Chicoxin. Cardiotropic agents such as neuquinone; kes-1-stercon, testosterone enanthate, l-liethisterone, methylestrenolone, meth-1-cinol-1-valerin 1% Q-nis-1-radio-
I'1 bolone agents such as ole, ethinyl estradiol:
Hikumin A, Hikumin 1, Hikumin 1, or other Hikumins and Erninokarthof T, 1 Cole, Cholecalunfer 1-1-1, Otatonamine, Ribofurahin t'r*Coastyl, Hitamingari, Phosphate, Hisoruhin, etc. antitussive and expectorant agents: lysozyme and other anti-inflammatory agents; insulin and other antidiabetic agents: D-penicillamine, hestatin, rehamisol, carphenyl, planin, etc. Drugs: Other anticonvulsants: Antimalarials; plcostagran)-ins: Pancreatic por7in. Examples include herbal medicine extracts, anti-swelling ingredients, etc., and these medicinal ingredients may be used alone or in combination of two or more. Of course, these drugs may be used alone or in combination with the base ingredients listed in 1);
1-, isopropyl myristate, volip 1-copylene gelicol, crotamiton. The drug may be used by dissolving it in a dissolving agent such as conitylenocrycol, phanalene glycol, diethyl 1-1-1, or Shitubu Pill Acipe-1.9. In addition, (jL known transdermal absorption enhancers and stabilizers. Anti-aging agents, fragrances, antioxidants, reinforcing fillers. Additives such as fillers and adhesives are added as necessary. Additives include, for example, water-soluble commercial molecules such as polyhinyl alcohol, polyhinylpyrrolitone, polyacrylic acid, vinyl alcohol thread copolymer, polybutene, rosin, estercam, etc. Examples include adhesives such as esters, bulking inorganic fillers such as silica, kaolin, talc, and zinc oxide. 0.1 to 25 parts by weight, preferably 0.2 to 15 parts by weight, per 100 parts by weight of the dispersed material (hereinafter referred to as the dispersion base component).Additionally, various additives may be added as necessary. The agent is added in an amount of 5 to 20 parts by weight, preferably 7 to 15 parts by weight, per 100 parts by weight of the dispersion base component.Next, the method of blending the medicinal ingredients and additives will be described. The above-mentioned micro-1-roquel is added to orkanoboriso-1-coxane, which is the base component of the present invention, in an amount of 11
After drying, it is preferable to add the above-mentioned compounding chamber. Further, if necessary, additives may be added at the same time as or after the addition of the medicinal ingredients to the extent that they do not interfere with the crosslinking and curing of the organoboric acid. In addition, the medicinal ingredients and additives may be blended in the same tank used to obtain the base component described above, and the temperature is sufficient to be within the reaction temperature for obtaining the base component. The mixture of dispersed base ingredients and medicinal ingredients, optionally additives, as described above, can be applied to a flexible support such as polyethylene, polypropylene, polyphtadiene, ethylene-yellow acid, etc. Car combination. A film of polyhinyl chloride, polyester, nylon, or a porous body made of the same 9 Foam and a breathable sheet-like material such as paper, cloth, non-woven fabric, etc. Coating (spread to a thickness of 50 to 2 fins, preferably 100 to 1 fin, at room temperature to 150 degrees Celsius, preferably 40 to 80 degrees Celsius)
Crosslinking and curing is carried out by heating at C for 3 minutes to 24 hours, preferably for 15 to 40 minutes. After that, the surface was peeled off and treated with 1ii1.
Either cover with J-fan or a plastic film made of polyethylene, polypropylene, etc. and cut it into a desired size (11 iL) to obtain the object of the present invention, or spread it on a heat-stable support and heat it as described above. , a synthetic resin that is subjected to cross-linking and curing treatment and then used as the desired purpose. After covering with a support such as cloth, the material may be pressure-transferred and cut into a desired size. 2 can be selected as appropriate depending on the intended support. Next, the effects of the patch of the present invention will be described. The patch (=J drug) of the present invention obtained as described above has appropriate adhesion and adhesive strength to the skin of the human body, and due to the water retention ability of the microhydrokel, it is It lasts for a long time, and there are no side effects such as discomfort even if you continue to apply it for a long time, and it does not cause hair pulling, corner tracing, or breakage when it is removed, and it can be removed once applied. +1
It has great features such as the initial adhesion and adhesion strength even after applying it four times. Also, drug release +! It has very good Ig, long-lasting properties and percutaneous absorption, making it very useful industrially as an ideal anti-aging drug. It goes without saying that the glue of the present invention is based on the characteristic base components as described above. This will be explained in the following test example regarding the above-mentioned Rhino fruit. In the test examples, the terms "Examples" and "Reference Examples" refer to those described later in the main point 11 of the present application.
There is C. Test Example 1 Usability Comparison Test Ten subjects were asked to use Examples 1 and 2 of the present invention, commercially available anti-inflammatory and analgesic plaster A (base: 1% natural) as a comparative example.
Mu No. Synthesis 11 Mu, the drug contains No. methyl sudylate) and poultice B (gelatin, 10 kaolin (water soluble 1'
+J molecular-based drug and drug containing methyl tylate) were applied to the surface of the forearm (=t L,
It was peeled off after 8 hours. -1.Each item L1 listed below was tested and determined. The results are shown in Table 1, and Examples 1 and 2 of the present invention were commercially available anti-inflammatory analgesic plaster Δ and poultice 13.
Compared to
Unfortunately, this is something that makes me wonder about the practicality of the present invention. Test item a) Cold sensation Those with a cold sensation... ◎ Those without a cold sensation... × Mouth) Fast-acting (time to start feeling irritation) within 5 minutes
・・・◎ Within 5 to 10 minutes ・・・0 10 minutes creation” 2 ・ ・ ・ ×c) Persistence (time until irritation disappears) 4 hours or more ・・・◎ 2 to 4 hours ・・・0 2 Within hours ・・・× d) Adhesive paste A・J with oil U7 well adhered to the inside ・・Those that have peeled off at the part of Or+li°1) ・・Those that have peeled off within 0 days ・・× P) Strength of stimulation: Very strong...◎ Strong...○ Weak...× 1\) Peeling 11. J's pain easily peels off...◎ I feel the bu1h...○ There is a strong 911...× 1.) Peel! ijl+Ancient word for time (・j 5 times or more 10Q) 4" eye 'j き...◎ I can't get it...× Table 1 Result of See 1) As is clear, this one head invention paste ii; 1
)il: (a, i ?Rei(・ki, 1fflsuJ l'
L, persistence 2 adhesion, strength of stimulation. Peeling 1i1111. 'l']+'+i h -'l'l
:'ill ll, "10) 4r results for l'G paste A・1 (i-).
and 2 (25" The residual moisture rate was calculated based on the 1.1 change in width. The results are shown in Figure 1. (In the figure, 1 represents Example 1, and 2 represents Example 1. 2, C is commercially available product C, D
As is clear from the results, the product according to the present invention had better water retention than the commercial product. Test Example 3 Human transdermal absorption test Subjects were five healthy male volunteers.
The product of Example 3 according to the present invention and the product of Reference Example 1, which were cut to a size of 1 x 2 cnl, were bonded continuously for 8 hours, and the remaining drug solution in the adhesive was removed by high-speed liquid. It was quantified by chromatography, and the transdermal absorption rate (%) of the drug was determined from the ratio to the initial M content. The test results are shown in Table 2, and the product according to the present invention had very good drug release properties and transdermal absorption, and demonstrated the usability of the present invention. , 1;, 2 Test Example 4 In-water IJ test Example 4.5 and Comparative Example 2 were used to measure 11.1 l volume of in-1 methacin in water. Each linsol was immersed in 4×4 (III) J of pure water at 30°C, and the immersion rate and release rate (
%) was investigated. However, when comparing the results of Examples 4, 5i, and 1 according to the present invention to Example 2, the result is much smaller than Example 2.
Shi7 Noko. lg1 6s 5 back 9. Urugutsu man u・(n1 man easy tA
L-Ko, Shi' Luca Novorino 1 To 1 - Rin and Shrine Kano High 1
The present invention is characterized in that the base component is an organopolysiloxane obtained by reacting 1-1 dieneborsiloxane in the presence of platinum or a platinum compound, and that the present invention is characterized in that the present invention is characterized in that the base component is an organopolysiloxane obtained by reacting 1-1 dieneborsiloxane in the presence of platinum or a platinum compound, and that the present invention is characterized in that Mitsu 1 Cohitotrochel is dispersed therein. It can be said to be a new type of patch medicine that eliminates the drawbacks of the medicine. Hereinafter, the present invention will be explained in more detail with reference to Examples. However, it goes without saying that the present invention is not limited to the examples. In addition, in the examples, all parts indicate vehicle volume parts. Example 1 End f'u11 of 4,000 centimeters at 25°C
'1゛S1 formula-3032121'V (θ Kikutoguchi silicone!RJ') where Jk is a noorkanobolysiloxane having a hinyl structure. platinum-containing YLF organohytrodiene polysiloxane with
, -5822+3 ((Higashiguchi Silicone 4\IJ)
The mixture was stirred and mixed at 30°C for 10 minutes. On the other hand, Sumikagel S-50 ((41 Sumitomo Chemical J)
45 parts of organobolin after absorbing twice as much distilled water.
-I was added to the xane mixture for 1 min.-
Rii (a-menthol 6 parts, male thylic acid nonal 6Fl (
, 5 parts of camphor were added and mixed for 20 minutes until homogeneous. Soak the resulting mixture in water. 1. Spread it on a permeation-treated nonwoven fabric to a thickness of 1 mm, heat for 25 minutes to harden, cover the surface with cetophane, and cut into the desired size. It was made into a product. When I used this as an example to the human body, I found that it was cold (・・
3 lasts a long time and is useful as an anti-inflammatory 5iW patch for non-electronics. Example 2 KIE which is a dicanoborin loxane having a hinyl group at the end of 4,000 centivoices at 25°C
-106L TV [(+lll manufactured by Shin-Etsu Chemical) 100 parts and 250 at 25°C. 5822B (it
(manufactured by Toshiba East Exit Ni-1-N)] and 1) W fi were mixed at 30°C for 10 minutes. - Camphor Part 5 I-IM
3 (10 (it (1) manufactured by Sanyo Chemical Industries) and 20 of its own weight
It was made into a microhydrogel by absorbing 0x distilled water. 80 parts of this Miku 1'' Hiker 10 Kel was added to the mixture and well dispersed. Next, p-men!・Add 0 parts of methyl salicylate, 10 parts of camphor, and mix for 20 minutes to make it homogeneous. Spread the resulting mixture on a water-impermeable nonwoven fabric to a thickness of 1 tuna. The product was spread and cured by heating for 30 minutes, and the surface of the product was covered with a polyethylene film and cut into desired sizes to obtain a product.When used on the human body, the results were the same as in Example 1. Example 3 At 25°C 4.(100 centipoise end groups
13 is a silorganoborisiloxane having /A.
-] 06 L TV [11 Shin-Etsu Chemical] 100 parts and TSIJ-30321, platinum-trained organohydrodiene polysiloxane with both terminal groups having 1) 1 hydrogen atom and 600 to 1,000 centibodies at 25°C. 9 parts of i'V-+3 ((! Manufactured by Masutoguchi Silicone) were stirred and mixed at 25°C for 10 minutes. ]
Absorbed distilled water of 15θa) from my car.
hi] 1” Kel. Microbiology of the above mixture)
Bow-1 Kelt;ot+++ added, well dispersed 1! Ta. Add 5.7 fiIX of 1 fluorine to the mixture dissolved in 15 parts of Coach Synch Recall and mix for 15 minutes.
to make it uniform. The resulting mixture was diluted to a thickness of 500μI.
IL-polyphthalamic acid 1. to 100ph℃)φ
It spreads out for 25 minutes! After curing with 4j, the surface was covered with polyethylene film J to prepare a product.゛Example 4 After 70,000 senna voices at 25°C! YE-, which is a noorkanoborisoloxane in which the AI group has a hinyl group;
562 (iC (manufactured by i11 Toshiba Tree Line) 100
part and 25゛C [i 00 ~ l, (both ends of HIO senna voice υHi, 1, !A'h<store 1y1- hydrogen field r
Orcahyde L Coso Emboliso 1J key ~
Suuyu/te Shirokanekin Ijzume'FS Iro-:3032
It'r v -+3 (manufactured by t111 Toshiba Corporation) 8 parts and stirred at 25°C for 1 minute for 1 minute.
l arranged marriage 26-0-power, -bikuakifu 4SLlj■
250 (manufactured by Steelmaking Pai6 Co., Ltd.) was absorbed into a microhydrogel of 250 (iλ) of distilled water. 80 parts of this microhydrogel was added to the mixture and well dispersed for a while. Next, 6 parts of dissolved -U indomethacin was added to crotamiton 60;9 and mixed for 10 minutes to make it homogeneous.The obtained 4-6 compound was spread on a non-woven fabric treated to be impermeable to water to a thickness of 2 (lO). , and cut, and the surface was covered with secophane to prepare a product.Example 5 T S LC, which is an orkanoboricoxane having a terminal t'lj:j group or a hinyl group with 4,000 centivoices at 25°C. -3032R'VV [manufactured by f-stock Higashiguchi Silicone] 100 parts and 250 centivoices at 25°C, organohytrosienbolyshi i:I glycane with active hydrogen atoms at both ends &j:j group containing platinum in YE -58
228 (i + Kikuto Higashiguchi Ricoh) 7 parts and mix well at 45℃ for 20 minutes.Meanwhile, Sumikakel N-10
0 (manufactured by Sumitomo Chemical) was used to absorb 200 times its own weight of distilled water to make Miku (for "I Kel"). To the above mixture, 62 parts of this "Miku 1-1 Hi 1-1" Kel was added. Well minutes &
I let it happen. Tsuriji 1 evening 5 H1; 1 experience!
Add 5 tH1 of indomethacone (1 l) and mix well for 30 minutes. Spread the mixed mixture on polyphthalene-1 to a thickness of 200 μm, and
5) Cover the surface with release paper after heating to harden for 110 minutes.
It was a classy item. Example 6 1. at 25°C. HIO sennavoice i') i: K which is a diorganopolysiloxane having an l group or a vinyl group
K-1031:2'rV C(lJi-[chemical reaction 100 ff1i to 25°C, both terminal groups of 602 centimeter voice have active hydrogen atoms.''
Nimbolisiloxane containing platinum Yl.58
22B (f + manufactured by Kikuto Higashiguchi Ricoh) and 5 (1'c) were stirred and mixed for 10 minutes. On the other hand, Sumikagel S-50 (
ill (manufactured by Sumitomo Chemical) was used to absorb 200 times more distilled water than the vehicle's own vehicle to create a micro hydrokel. 70 parts of this Microhuman 1 cogel was added to the mixture and mixed well. Next, flurhyprofen 5 and 2 t'jl> dissolved in diethyl alcohol 1.+or+++ were added and mixed well for 15 minutes. The resulting mixture was transferred to a nylon support (
Product name Niai Nil N] O'1 (manufactured by Asahi Kasei Co., Ltd.) 100>
It was spread to a thickness of p and cured by heating for 25 minutes. The surface was covered with a 1" fan and cut into a desired size to produce a product. Example 7 X-32-465, a diorganopolysiloxane with L102 centipoise at 25°C and a vinyl end group
-2A (+48) Shin-Etsu Chemical 3100 parts 60 at 25℃
A platinum-containing organohydrodieneboline U xane in which both end groups of 2 centibodies have active hydrogen atoms.
-32-465-213 (t+2) manufactured by Ikoshu Kagaku] 95
of the mixture and mixed with stirring at 25° C. for 10 minutes. -・Method, Zanueso I-IM-300 ((1 station) Sanyo Chemical J was made to absorb 300 times its own weight of distilled water to make a microhydrogel.The mixture was added to this microhydrogel 65
part was added and well dispersed. Next, 0.05 part of hetamethacin valerate and 1 part of propylene glycol were added to
Mix well for a minute. Spread the resulting mixture on release paper to a thickness of 1
00PIIt, heated and cured for 30 minutes, covered with a polyethylene film, pressure-transferred, cut to desired size and molded into 1v1 pieces. At 25°C, the end of 700 centimeter voice is 17:: and the vinyl group is combined with Orkaba (1'u diembolysilyl coquinine Kl>-104G+':i ((41)
Shin-Etsu Chemical Layer) 100 parts and 1 group of 80 sennan at 25°C are activated fll: Hydrogen atoms are hydrogen atoms containing platinum in polysiloxane (:;
+t104 ((A'JI Shin-Etsu ``γ゛! l<'!,,
+ 101(1) and mixed well for 10 minutes at 20'C. On the other hand, 250 times the amount of distilled water was absorbed into Sumikagel S-50 (manufactured by Sumitomo Chemical) to make a micro hydrokel. Add 5.5 parts of empiritamol and 4 parts of empiritamol, mix well for 15 minutes until homogeneous.
It was spread to a thickness of 11 mm and heated for 35 minutes.
C. The surface was covered with E11 pattern paper and cut into the size of the area '-i) to prepare a product. Example 9 KE-1 is a diorganopolysiloxane with vinyl end groups of 4,000 centipoise at 25°C.
0G LTV (i11 Shin-Etsu Chemical 14) 100 copies and 2
Y1≦nee 5822B (manufactured by Higashiguchi-Silico-7 Co., Ltd.: l 9F71i c!: 'c 40 parts (10 minutes IR7 stirring t'l' ?Jg combined).Meanwhile, absorb 30υi1) of distilled water of its own weight in Sumikagel N-100 (ill Sumitomo Chemical) and mix it with Miku I Cohi1. It was made into Kawaji I Kel. 50 parts of 10 Kel were added to this mixture to make a volume of 11. Next, ALC 1J Fenutsk 47 dissolved in 15 parts of Shiitsubu 1J Pill Ash was added to the mixture.
t (+ was added and mixed well for 20 minutes. 1q of the mixture was spread on a polybutadiene sheet to a thickness of 100/L1aOJ) and cured by heating for 20 minutes. The surface was covered with a polyethylene film, and the product was cut into a desired size. Example 10 X-3, a shimelcanoborisilyl IJ xane with a terminal or hinyl group of 1,012 senna voices at 25°C
2-465-2Δ((II (4t! Made by A Chemical) 100
X-32-465-2 with platinum-containing -3' diembolysiloxane in which both end groups of the 602p-no-voice have 1 kyoko of active hydrogen at 25°C.
1J (f stock made by Shin-Etsu Chemical) Add 100 aB and 30°
The mixture was stirred and mixed at C for 5 minutes. -・Power, Sumika/7-le S
-50 (F41 manufactured by Sumitomo Chemical) was used to absorb 250 cans of 11n of 7mine distilled water to make Miku l'hi 1-rockel.
100 parts of this microhuman IJ Kel was added to the L compound, and the mixture was diluted to 1 part. Tsuri L: I) Dissolved in 15 parts of y mittens I
Added 9.7 tiB of Flurhyp and mixed for 15 minutes. Spread the mixed mixture in water to a thickness of 1 mm on a non-woven fabric treated with impermeability, heat for 20 minutes to harden the surface, and then cut the mixture to the desired size using a fan. It was made into an i-shi product. Reference Example 1 A known poultice with the formulation described in 1. was prototyped and designated as Reference Example 1 of a poultice containing Ke-1-profen. Base component: Seratin 7 Carpoxymethyl cellulose 1-sugar 2 Borihinyl alcohol 3 Kaolin clay
20Titanium oxide 5 Water 35 Ketop 1'phen 3 Ethylene glycol 5 Glycerin 20 (Combined 1 oor; +s) [Na Shiropa 2zo point], 2. Combination 1; 1; Shifunan
Giant 1.1 millimeter heel 1
Le, '3 cri 1! reno
20 water
;)) (power;
201'iQ J-ta:,
4 Cal j-1) 7 Nonorse Katagawa, I Su
2-run 1 Tutanon 3 (combined AL
ll) 0 copies) 4.During the drawing, 1k11ji; 1ming drawing mouth 1st; Scalp (J mountain 1 lili paste fl specialized Ni was placed on Ji, and the person was left alone for a while. Jl-filtrate)・'7) 1'1° remaining
reduce the rate. Figure 2 ε, 1: , l,: 1% and non+6 cases of pasting i・j
Medicine in water y3E Shinoko”IQ) ?4 /H’j 1
The release rate of the drug is >l −1' 4 between il and i. Figure 1 71 13 12 1fi 20 241h (
Ibo) Figure? 1 2:'84 ri [4'/8! 1
Soaking for 15 hours (1 bo)'' - Continued - 1 - T = Written (Spontaneous) 1. Indication of the case 1982 Patent 1 No. 198253 - 2. Name of the invention New patch drug 3. Person making the amendment Relationship to the incident, Patent applicant address: 408 Daikan-cho, Tosu City, Saga Prefecture (■84
1) The following corrections will be made to the specification of the application. ■ No. 11 in the column “3. Detailed description of the invention” in the specification
In the last line of the page, ``pimeprofen'' is corrected to ``]-ibuprofen piconol''. ■ Insert [loxoprofen, clidanasoc] next to "Amfuenasoc" in the first line of page 12. ■ Insert scopolamine monohydrobromide, lorazeham, haloperi[-l] after ``chlorpromazine'' in the second to fourth lines of ``Ibid., p. 12''. ■ Insert [hydrocortisone butyrate propionate] next to "fludroxycordide" in the seventh line from the top of page 12. ■ Insert ``1 nicorandil'' after ``1 nitroglycol'' in lines 2 to 5 of ``Ibid.'', page 14. ■ Insert ``1-carteolol, propranolol'' after ``1-theophylline'' in the 9th line from directly above No. 14. ■ 1 Nitrazebum, page 14, line 10 from the top.''
Then insert 1-clonacebam. ■ Insert "1 niskucilam" after "cyclohalchtal" in the 5th line from page 14 of the same page. ■ Insert "1 Zalftamol, Procarterol" next to "Hisoruhin" in the 5th line from the top of page 15. [Phase] Insert "1 Kurihenclamide" after "Inturin" in "7th line from the top of page 15". ■ Ibid., p. 15, lines 2 to 10, 1-drug/llI
: Next to J, insert a gout treatment agent such as 1-colchicine, an antispasmodic agent such as dimethyl sulfate, methylscopolamine, etc. @ Same, page 15, line 12 from the top, 1 - Anti-Crushing Punishment -
1 is replaced by 1-Anti-ulcer agents such as cimedicine, ranitidine, famotidine, etc. 0 Same, page 16, 3rd line from the top, next to [Fragrance-1]
Insert "mineral oil". (2) "10.1-25 parts by weight" in the 6th line from the top of page 16 is corrected to "IO, 03-25 parts by weight". ■ Same, page 16, 1. to 5th line 10.2-15
Ichiyagawa 5'' is compressed with IO, (13 to 15 parts by weight). [Phase] Insert the attached sheet [Examples 11 to 18] next to Example 10 on page 35. Implementation Example lI An organopolysiloxane with a vinyl end group of 80,000 centivoices at 25°C.
30' 8 at C
Mix well for a minute. Next, Sumikagel S-50 (manufactured by El Sumitomo Chemical) was made to absorb 250 times its own weight of distilled water to obtain a microscopic volume of 10 kels. To the mixture was added 100 parts of Gono Miku 1" human kelp and well dispersed. Then, it was well dispersed. 10 parts of liquid paraffin and scopolamine hydrobromide o. Example 12 MDX is a siorganoborisiloxane in which the terminal group of the 25"C゛ζoo, ooo centivoice has a vinyl group. The product is cured by heating for a minute, and the surface is covered with cellophane and cut into a desired size to produce a product. −
100 parts of 4-4210 (manufactured by Tau Corning) and 25°C
A 1-, 200-centivoice polysiloxane having active hydrogen atoms at both end groups was thoroughly mixed with 4 parts of a platinum-containing curing agent at 30 DEG C. for 8 minutes. Next, 250 times its own weight of distilled water was absorbed into Sumikagel S-50 (11 manufactured by Sumitomo Chemical) to form a microhydrogel. 100 parts of this microhydrogel was added to the mixture and well dispersed. Next, liquid paraffin was added. 10 parts of hydrocortidane butyrate propionate were mixed and dispersed for 20 minutes.The resulting mixture was spread on a water-impermeable nonwoven fabric to a thickness of 1 inch, and heated for 20 minutes to harden. The U back surface was covered with cellophane and cut into the desired size to produce a product.Example 13 The end group of 80,000 centivoice at 25°C was hinyl W.
MDX-4- which is a dikanoborisiloxane having
4210 (Tau Corning Co., Ltd.) 100 Rli and 1 at 25°C, an organohydrodiene polysiloxane containing active hydrogen at both end groups of 200 centipoise and 4 parts of platinum-containing curing agent at 30°C. (Mixed for 1 minute. Next, absorb 250 times the amount of distilled water in Sumikagel S-50 (manufactured by El Sumitomo Chemical).
・It was named Roquel. One part of this MIG 111 Hi and 100 parts of Roquel were added to the mixture and well dispersed. Next, 10 parts of liquid paraffin and 0.2 parts of clonazepam were mixed for 20 minutes.
I made it to 1. The resulting mixture is spread on a water-impermeable nonwoven fabric to a thickness of 1 am, heated for 20 minutes to harden, and the surface is covered with cercophane and cut into desired sizes. And so. Example 14 Ml)
4 4210 (manufactured by Tau Corning) l [ ] o part and 2
At 5°C, an organohydrodiene polysiloxane having 1 and 200 centivoice end groups each containing an active hydrogen radical was thoroughly mixed with 4 parts of a platinum-gold curing agent at 30'C for 8 minutes. Next, it was made into Sumikagel S-50Cf microhydrocel. This micro hydrokel 1 is added to the mixture.
Add 0.00 parts and make sure it is well dispersed. Next, 10 parts of liquid paraffin and 0.8 parts of pindolol were mixed and dispersed for 20 minutes. The resulting mixture is soaked in water, spread on an impermeable non-woven fabric to a thickness of 1 inch, heated for 20 minutes to harden, cover the surface with cellophane, cut into desired sizes, and form the product. did. Example 15 MDX is a diorganopolysiloxane with a vinyl end group having 80,000 centibodies at 25°C.
-4-4210 (manufactured by Tau Corning) 100 copies and 2
An organohydrodiene polysiloxane of 1 to 200 centivoise in which both end groups are active hydrogen atoms was thoroughly mixed with 4 parts of a platinum-containing curing agent at 30°C for 8 hours. Next, Sumikagel S-50 (F41 manufactured by Sumitomo Chemical) absorbed 250 times more distilled water than the own car.
It was set to 0 Kel. Add 11 microorganisms to the mixture.
00 parts were added and well dispersed. Next, liquid paraffin 1
0 parts and 1 part of glyhenclamide were mixed and dispersed for 20 minutes. The resulting mixture was spread on a water-impermeable nonwoven fabric to a thickness of one fin, heated for 20 minutes to harden, and the surface was covered with cellophane and cut into the desired size to form a product. . Example 16 MDX-4, a diorganopolysiloxane with vinyl end groups at 80,000 centipoise at 25°C.
-4210 (manufactured by Dow Konink) at 25°C and 4 parts of a platinum-containing curing agent in an organohydrodiene polysiloxane containing active hydrogen atoms or one anchor at both ends of 1 and 200 centivoids at 30°C. The mixture was thoroughly mixed for 8 minutes. Next, Sumikagel S-50 (manufactured by Sumitomo Chemical Co., Ltd.) was made to absorb 250 times as much distilled water as the own car to make a micro hydrokel. 100 parts of this micro 1U gel was added to the mixture and well dispersed. Next, liquid paraffin was added. Part IO and 0.2 parts of colchicine were mixed and dispersed for 20 minutes at 7jfs.The resulting mixture was spread on a non-woven fabric treated to be impervious to water to a thickness of 1 cup, and heated for 20 minutes. The product was cured by covering the surface with cellophane and cut into a desired size to produce a product.Example J7 A dikanoborisiloxane having a vinyl group as an end group with 80,000 centivoices at 25°C.
X-4-4210 (manufactured by Tauconinck) 100 copies and 2
An organohydrodiene polysiloxane having 1 and 200 centivoices in which both end groups are active hydrogen atoms was thoroughly mixed with 4 parts of a platinum-4 curing agent at 30'C for 8 minutes. Next, Sumikagel 5-50 [41 manufactured by Sumitomo Chemical] was made to absorb 250 times as much distilled water as the own car to form a microhydrokel. 100 parts of this microhydrogel was added to the mixture and well dispersed. Next, 10 parts of liquid paraffin and 10 parts of cimetidine were mixed and dispersed for 20 minutes. The resulting mixture was spread onto a water-impermeable nonwoven fabric to a thickness of 1 cm.
The product was spread out and cured by heating for 20 minutes, and the surface was covered with cellophane and cut into a desired size to obtain a product. Example 18 MDX-
4210 (manufactured by Krakoning Co., Ltd.)], 001 liter (and 4 parts of a platinum-platinum curing agent at 25°C with an organohydrodiene polysiloxane in which both terminal groups of 1 and 200 centivoise are active hydrogen Ijft'). at ℃8
Mix well for a minute. Next, Sumikagel S-50 ((41
(manufactured by Sumitomo Chemical) to absorb 250 times its own weight of distilled water to form a micro hydrokel. Add 1 of this Miku and 1 of Ihi to the mixture.
Add 100 parts of ``Kel'' and mix well. Next, the flow is 0.
J paraffin ro ar+ and 10 parts of ranitidine were mixed for 20 minutes. The resulting mixture was spread on a water-impermeable non-woven fabric to a thickness of l+u, hardened by applying pressure for 20 minutes, and cut into the desired size using cellophane. It was made into a product.

Claims (1)

[Claims] 1. A diorganopolysiloxane whose terminal group is a vinyl group and an orkahydrodiene polysiloxane whose terminal groups are active hydrogen atoms are reacted in the presence of platinum or a platinum compound. A new adhesive patch characterized in that the resulting organopolysiloxane is used as a base component, microhydrogel is dispersed therein, and a medicinal ingredient is mixed therein. 2. The novel medicinal patch according to claim 1, wherein the diokanopolysoloxane whose terminal group is a vinyl group has a viscosity of 600 to 700,000 centivoices.